Lysosomes are often described as the recycling centers of the cell. These acidic, membrane-bound compartments contain a cocktail of degradative enzymes capable of breaking down proteins, lipids, damaged organelles, and other cellular debris into their basic building blocks, which can then be reused. Because nearly every cellular waste stream ultimately passes through the lysosome, even partial impairment of these organelles can cascade into widespread dysfunction. Lysosomal damage is a hallmark of aging, neurodegenerative disease, and ischemia-reperfusion injury, the tissue damage that occurs when blood supply returns to tissue after a period of oxygen deprivation. Yet despite decades of research into lysosome biology, the mechanisms that maintain lysosomal integrity under stress have remained incompletely understood.

The prevailing models of lysosomal maintenance have centered on autophagic lysosome reformation, a process in which lysosomal components are salvaged from autolysosomes, hybrid compartments formed when autophagosomes fuse with lysosomes, and reassembled into new functional lysosomes. The new study demonstrates that B-fission operates independently of this canonical pathway. When lysosomes are damaged by hypoxia-reoxygenation stress, they do not simply wait to be recycled through autophagy. Instead, they actively participate in their own rescue, generating membrane buds on their surface. These buds progressively extend from the parent organelle and then undergo scission, pinching off to yield small, fully functional lysosomes. The undamaged components of the impaired parent organelle are thereby reorganized into daughter organelles, leaving the damaged material behind to be dealt with separately.

The mechanistic heart of the discovery lies in the identity of the scission machinery. Budding and fission events in cells generally require a specific set of proteins to constrict and sever a membrane neck. For mitochondria, that machinery is well known: the dynamin-related GTPase DRP1, recruited to the mitochondrial outer membrane by adaptor proteins such as MFF, constricts and divides mitochondria during mitochondrial fission. The researchers found that damaged lysosomes co-opt this exact mitochondrial division apparatus. MFF, a fission adaptor normally resident on mitochondria, is delivered to lysosomes, where it recruits DRP1 to drive the scission of the budding lysosomal membrane. In other words, the cell repurposes the mitochondrial division machinery to divide a completely different organelle.

How does MFF get to lysosomes in the first place? The answer involves mitochondrial-derived vesicles, or MDVs. These small vesicles bud from mitochondria and are known to transport selected mitochondrial cargo to other cellular destinations, most notably to peroxisomes and to autophagosomes during mitophagy. The new work shows that under hypoxia-reoxygenation stress, mitochondria generate MDVs carrying MFF. These MFF-positive vesicles then travel to damaged lysosomes and deliver their cargo, providing the adaptor that lysosomes need to assemble a functional DRP1-dependent scission apparatus. This is a striking example of organelle-to-organelle communication, with mitochondria effectively supplying the tools that allow lysosomes to renew themselves.

Two additional proteins complete the regulatory circuit. The first is MIRO2, a mitochondrial outer-membrane GTPase better known for its role in linking mitochondria to microtubule-dependent motor proteins and regulating mitochondrial motility. The study shows that MIRO2 promotes the formation of MFF-positive MDVs through a direct physical interaction with MFF, acting as a gatekeeper that selects MFF as cargo for vesicular export. The second is ITM2C, a lysosomal membrane protein that binds MIRO2. By tethering the MFF-carrying vesicles to the lysosomal surface, ITM2C guides and anchors them at the correct destination, ensuring efficient MFF delivery and, consequently, efficient B-fission. The researchers describe this stress-responsive pathway as the ITM2C–MIRO2–MFF–DRP1 axis, a chain of interactions that connects the mitochondrial surface to the lysosomal scission machinery.

The physiological relevance of this pathway was demonstrated through manipulation of AMPK, the AMP-activated protein kinase, a master metabolic sensor that is activated when cellular energy levels fall. When cells were treated with AMPK activators such as 991 or metformin under normal oxygen conditions, MFF-dependent lysosomal B-fission was promoted, indicating that AMPK is a physiological trigger for the pathway. Conversely, when AMPK was inhibited with dorsomorphin during hypoxia-reoxygenation, B-fission was suppressed, and lysosomes presumably remained in their damaged state. This pharmacological control establishes AMPK as a central node that couples energy stress to lysosomal renewal, and it raises the intriguing possibility that widely used drugs such as metformin may partially exert their protective effects by boosting this lysosome-repair program.

The implications of the work extend across multiple fields. For researchers studying ischemia-reperfusion injury, the identification of a stress-activated lysosomal renewal pathway offers a mechanistic explanation for why lysosomal damage is so consequential during heart attack and stroke, and it suggests that enhancing B-fission pharmacologically could protect vulnerable tissues. For the lysosome biology community, the finding adds a new mode of organelle maintenance to the established repertoire of autophagic lysosome reformation and endosomal sorting. And for cell biologists more broadly, the demonstration that MDVs can ferry a fission adaptor between organelles, and that a mitochondrial division machine can be installed on lysosomes, underscores how fluid the boundaries between organelle systems really are. Mitochondria, long appreciated as signaling hubs that communicate through calcium, reactive oxygen species, and metabolites, now appear to communicate through physical transport of division machinery as well.

The technical elegance of the study lies in its dissection of each step of the pathway. By showing that MIRO2 binds MFF directly, that MDVs carry MFF, that ITM2C tethers those vesicles to lysosomes, and that DRP1 recruitment to MFF-decorated lysosomes is required for scission, the authors built a complete causal chain from mitochondrial membrane to lysosomal division. Disrupting any single link, whether by removing MIRO2, ITM2C, MFF, or DRP1, or by blocking AMPK signaling, compromises the ability of stressed cells to regenerate functional lysosomes from damaged parents. Conversely, activating AMPK under baseline conditions is sufficient to initiate the program even without hypoxic stress.

What remains to be explored is the breadth of this phenomenon. Hypoxia-reoxygenation is a particularly well-defined stress, but lysosomal damage arises in many contexts, including exposure to aggregate-prone proteins in neurodegeneration, lipid overload in metabolic disease, and the normal wear of aging. Whether B-fission operates in neurons, in cardiomyocytes, and in aging tissues in vivo are pressing questions. There is also the tantalizing therapeutic prospect that metformin, already one of the most prescribed drugs in the world, could be repurposed or optimized to strengthen lysosomal quality control in diseases of lysosomal stress. For now, the study stands as a vivid demonstration that the cell’s repair strategies are more inventive than previously imagined: when a lysosome is damaged, the mitochondria deliver the scissors that let it cut its losses and begin again.

Hypoxia, or oxygen deprivation, is a hallmark feature of the tumor microenvironment that drastically reshapes cellular behavior, driving malignant phenotypes such as enhanced invasion, metastasis, and resistance to therapy. Understanding the cellular adaptations to hypoxia is essential, as these adaptations underpin the aggressiveness and therapeutic recalcitrance of many cancers. The study by Peng et al. delves into this critical aspect by uncovering how lncRNAs act as pivotal molecular mediators in HCC cells’ response to low oxygen levels, potentially offering a new vantage point for therapeutic intervention.

Long noncoding RNAs, once dismissed as transcriptional noise, have emerged as potent regulators of gene expression and protein function. These molecules, exceeding 200 nucleotides in length, do not code for proteins but can interact with DNA, RNA, and proteins to orchestrate complex regulatory networks. In cancer biology, lncRNAs frequently operate as oncogenes or tumor suppressors, with their dysregulation profoundly affecting tumor initiation and progression. The identification of RHPN1-AS1, an lncRNA specifically upregulated under hypoxic conditions in HCC, marks a significant step in delineating how tumor cells exploit noncoding RNA machinery to survive and thrive in hostile environments.

Peng and colleagues employed an integrative approach combining transcriptomic profiling and molecular biology techniques to elucidate the function of RHPN1-AS1 in HCC. Their findings reveal that RHPN1-AS1 expression is markedly elevated when HCC cells experience hypoxia, a phenomenon rarely seen in normal liver cells. This differential expression pattern points to a specialized role for RHPN1-AS1 in hypoxia-driven cancer progression, potentially making it a biomarker for aggressive disease phenotypes.

At the mechanistic level, the authors uncovered a direct interaction between RHPN1-AS1 and RPS15A, a ribosomal protein traditionally known for its role in protein synthesis. This interaction is particularly intriguing because it links a noncoding RNA to the ribosome’s structural components, hinting at a sophisticated regulatory axis that may influence translation under hypoxic stress. RPS15A has been implicated in various cancers, and its functional modulation by RHPN1-AS1 adds a new layer of complexity to its contribution to tumor biology.

Further examination revealed that the RHPN1-AS1/RPS15A complex promotes HCC cell proliferation, migration, and invasion, all of which are fundamental steps in cancer progression and metastasis. Notably, the silencing of RHPN1-AS1 significantly attenuated these malignant phenotypes, underscoring the potential of targeting this lncRNA for therapeutic gains. The interplay between RHPN1-AS1 and RPS15A under hypoxic conditions appears to reprogram the translational machinery, favoring the synthesis of proteins that support tumor growth and survival.

The research also sheds light on the downstream signaling pathways affected by this interaction. The RHPN1-AS1/RPS15A axis appears to activate hypoxia-inducible factor (HIF)-mediated pathways, further enhancing the hypoxic response and creating a positive feedback loop that exacerbates tumor aggressiveness. This insight reinforces the centrality of hypoxia-driven molecular circuits in cancer progression and highlights the potential of disrupting this axis to break the vicious cycle of tumor adaptation.

Importantly, the specificity of RHPN1-AS1’s effect on HCC cells under hypoxia presents a therapeutic window that could be exploited to minimize off-target effects. Therapies designed to block RHPN1-AS1, or disrupt its interaction with RPS15A, might preferentially target cancer cells in the hypoxic niches of tumors, sparing normal tissues where oxygen levels and lncRNA expression differ substantially.

This discovery paves the way for a new class of anticancer strategies centered on noncoding RNA biology. Unlike conventional chemotherapy and radiation, which broadly target rapidly dividing cells, lncRNA-based interventions promise a more tailored approach, directly modulating molecular interactions essential for tumor survival. Such precision medicine strategies could revolutionize HCC treatment, a field in dire need of novel, effective therapies.

Beyond its therapeutic implications, the study by Peng et al. contributes to the broader understanding of ribosome biology in cancer. The ribosome, once considered merely a molecular machine for protein synthesis, is now recognized as a dynamic participant in gene regulation. The interaction between lncRNAs and ribosomal proteins exemplifies this paradigm shift, revealing how noncoding elements can repurpose core cellular machinery to adapt to environmental stress like hypoxia.

The clinical relevance of these findings cannot be overstated. HCC frequently presents at advanced stages, where hypoxia-induced molecular mechanisms drive rapid progression and poor prognosis. By targeting the RHPN1-AS1/RPS15A axis, clinicians may gain a potent tool to halt or slow tumor growth, offering hope for improved outcomes in a patient population that currently faces limited survival prospects.

As the field moves forward, several questions arise. How widespread is the role of RHPN1-AS1 across different cancer types or stages? Are there additional ribosomal proteins or lncRNAs forming similar complexes that contribute to tumor biology? Addressing these questions will deepen our comprehension of cancer’s molecular underpinnings and expand the arsenal of molecular targets.

Moreover, the development of delivery systems capable of efficiently and specifically modulating lncRNAs in tumors remains a paramount challenge. Advances in nanoparticle technology, antisense oligonucleotides, and RNA interference therapeutics could facilitate the translation of these molecular insights into clinical interventions. The prospect of manipulating the tumor microenvironment at the RNA-protein interface represents an exciting frontier in cancer therapy.

In summary, the identification of long noncoding RNA RHPN1-AS1 as a critical promoter of hepatocellular carcinoma progression via its interaction with ribosomal protein RPS15A under hypoxic conditions marks a transformative milestone in oncology research. This discovery not only uncovers a novel regulatory axis integral to tumor adaptation but also highlights the therapeutic potential of targeting lncRNA-driven molecular interactions in cancer. As researchers and clinicians strive for breakthroughs against HCC, the RHPN1-AS1/RPS15A axis may well become a beacon guiding the next generation of precision medicine.

Subject of Research: The molecular mechanisms by which long noncoding RNA RHPN1-AS1 promotes hepatocellular carcinoma progression under hypoxic conditions through interaction with the ribosomal protein RPS15A.

Article Title: Long noncoding RNA RHPN1-AS1 promotes hepatocellular carcinoma progression under hypoxia through interaction with RPS15A protein.

Article References:
Peng, Q., Cai, YT., Ding, Q. et al. Long noncoding RNA RHPN1-AS1 promotes hepatocellular carcinoma progression under hypoxia through interaction with RPS15A protein. Med Oncol 42, 502 (2025). https://doi.org/10.1007/s12032-025-03049-w

Image Credits: AI Generated

HIF-1α functions as a pivotal transcription factor that governs an array of genes facilitating metabolic recalibration, immune modulation, angiogenesis, and survival pathways under hypoxic stress. The core of this regulatory control involves oxygen-dependent hydroxylation catalyzed by two classes of enzymes: prolyl hydroxylases (PHDs) and factor inhibiting HIF (FIH). Under normoxic conditions, these hydroxylases mark HIF-1α for proteasomal degradation and suppress its transcriptional activation domains. However, the precise sequence and gradation through which these hydroxylases are deactivated as oxygen levels decline were poorly understood until now.

Employing an integrative approach combining mathematical modeling, dynamic simulation, bifurcation analysis, and rigorous experimental validation, Wang’s team constructed a quantitative regulatory network that captures the stepwise activation of HIF-1α under diminishing oxygen tensions. Their model elegantly demonstrates that HIF-1α stabilization and activation do not occur as a binary switch but rather progress in discrete stages dictated by the differential sensitivity of PHDs and FIH to oxygen. This refined understanding illuminates how cells interpret the subtle hypoxic continuum—from mild to severe hypoxia—and mount graded adaptive responses accordingly.

At the initial phase of mild hypoxia, approximately 2% oxygen, prolyl hydroxylases are selectively inhibited. This inhibition results in the accumulation of HIF-1α protein by preventing its degradation and exposes the N-terminal transactivation domain (N-TAD). The partial activation conferred by N-TAD leads to transcriptional upregulation of genes primarily involved in glycolytic metabolism enhancement and immune response suppression. These early adaptations allow cells to optimize energy production and modulate their microenvironment in response to modest oxygen shortages.

As oxygen tension further decreases to moderate levels near 0.7%, factor inhibiting HIF (FIH) activity is also impeded. With FIH inactivation, the C-terminal transactivation domain (C-TAD) of HIF-1α becomes accessible, culminating in full transcriptional activation. This stage is characterized by robust induction of angiogenic factors, promoting neovascularization to restore oxygen supply. The activation of angiogenesis at this hypoxia tier represents a strategic cellular investment in long-term survival, facilitating tissue remodeling and vascular adaptation.

Under conditions of severe hypoxia, defined as oxygen concentrations below 0.5%, HIF-1α is fully stabilized and activated at maximal levels. This state triggers a crescendo of downstream effects, including accumulation of lactate due to persistent anaerobic glycolysis, acidification of the cellular microenvironment, and ultimately, the initiation of programmed necrosis pathways. This terminal response highlights the cell’s shift from adaptation toward sacrificial processes when oxygen deprivation becomes untenable.

Intriguingly, the study identifies microRNA-182 (miR-182) as a dynamic modulator that fine-tunes HIF-1α’s transcriptional output throughout these activation stages. Acting as a “sliding regulator,” miR-182 dynamically modulates the feedback loops involving HIF-1α, PHD-2, and FIH to sharpen the sensitivity and precision of oxygen sensing. This dual feedback architecture balances positive amplification and negative regulation, enabling cells to respond to fluctuating oxygen levels with remarkable fidelity and adaptability.

The implications of this tiered hydroxylase deactivation and HIF-1α activation model are profound. By unveiling distinct transcriptional configurations tied to precise hypoxic thresholds, the work provides a mechanistic blueprint for “precision targeting” within the HIF signaling cascade. Therapeutically, this opens avenues for designing phase-specific interventions, such as selective inhibitors targeting glycolytic enzymes during mild hypoxia or anti-angiogenic agents tailored for moderate hypoxic zones, enhancing treatment specificity and efficacy.

Moreover, the advances in oxygen-sensing technologies, including spatially resolved probes capable of mapping oxygen gradients deep within tissues such as bone marrow, offer exciting opportunities to apply these insights in vivo. Understanding the spatial hypoxic heterogeneity within tumors, and how different hypoxic niches activate unique HIF-1α transcriptional programs, can inform better stratification of therapeutic modalities. Such spatial hypoxia profiling may elucidate why certain regions of tumors exhibit differential drug resistance or support immune evasion, providing critical guidance for treatment planning.

The research further highlights the importance of integrating hypoxia compartmentalization into multimodal therapy design. By accounting for the interplay between drug diffusion limitations and distinct hypoxia-driven cellular adaptations, combination regimens can be optimized to circumvent compensatory resistance mechanisms. This integrated approach holds promise to transform current monotherapies, which often fail due to incomplete hypoxia targeting, into more robust, synergistic strategies capable of effectively disrupting tumor growth and progression.

Future exploration will undoubtedly focus on expanding this regulatory network to include additional noncoding RNAs, post-translational modifications, and metabolic feedbacks that intersect with the HIF pathway. Furthermore, dissecting how cyclic and dynamic hypoxia—rather than static low oxygen—modifies HIF-1α activation patterns remains a fertile area of investigation. These refinements will consolidate our molecular understanding of cellular oxygen sensing and adaptation, accelerating the development of hypoxia-based precision medicine.

In sum, this seminal study reframes the classical view of hypoxia adaptation from a simple oxygen sensor narrative to a complex, layered regulatory choreography driven by progressive hydroxylase deactivation and sophisticated feedback control. It offers both a conceptual and practical framework to decode cellular oxygen responses, paving the way for innovative diagnostic and therapeutic advancements in diseases characterized by hypoxic stress.

Subject of Research: Cellular adaptation to graded hypoxia mediated by HIF-1α regulatory networks.

Article Title: Progressive Deactivation of Hydroxylases Controls Hypoxia-Inducible Factor-1α-Coordinated Cellular Adaptation to Graded Hypoxia

News Publication Date: 1-Apr-2025

Web References: http://dx.doi.org/10.34133/research.0651

Image Credits: Copyright © 2025 Ping Wang et al.

Keywords

Hypoxia, HIF-1α, prolyl hydroxylases, factor inhibiting HIF, oxygen sensing, cell fate, angiogenesis, metabolic reprogramming, microRNA-182, tumor microenvironment, graded hypoxia, feedback regulation